Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds UT-Austin to Supply Chain, Expanding Capacity for CycloSam(R) Production

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the treatment of cancer and other diseases and conditions. The company today announced the qualification and addition of the nuclear reactor at the University of Texas at Austin to its supply chain for the production of Samarium-153, the active radioisotope used in QSAM’s therapeutic radiopharmaceutical drug candidate, CycloSam(R) (Samarium-153 DOTMP). CycloSam(R) is a potentially groundbreaking treatment for metastatic and primary bone cancer in adults and children. “As a radiopharmaceutical development company, it is important to be able to successfully replicate our production process across different nuclear reactors, which adds capacity to produce and supply CycloSam(R) and further diversifies our overall supply chain risk,” said Douglas R. Baum, CEO and co-founder of QSAM. “We have established a robust vetting and testing process to evaluate nuclear reactors to include in our supply chain. We are fully satisfied with the results and are pleased to incorporate UT-Austin into our network of qualified reactors. This addition will help us consistently and reliably produce CycloSam(R) for clinical research and, potentially, ultimate use by treating physicians and their patients.”

To view the full press release, visit https://ibn.fm/0XipF

About QSAM Biosciences Inc.

QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP), which is indicated for bone cancer pain palliation. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. For more information, visit the company’s website at https://QSAMBio.com.

NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.